RT Journal Article
SR Electronic
T1 End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2535
OP 2538
DO 10.21873/anticanres.17625
VO 45
IS 6
A1 NGUYEN, MINH DUNG
A1 GOROBETS, OLENA
A1 DJOUA, YANNICK JOEL
A1 ROSE-DITE-MODESTINE, JOHAN
A1 VINH-HUNG, VINCENT
A1 VERSCHRAEGEN, CLAIRE
A1 NGUYEN, NAM P.
YR 2025
UL http://ar.iiarjournals.org/content/45/6/2535.abstract
AB Background/Aim: Enzalutamide is a highly effective anti-androgen for the treatment of prostate cancer. Therapy can incur unbearable fatigue in elderly patients, which might require a reduced dosage. However, the value of reduced-dose treatment to improve the long-term tolerability and to decrease the risk of toxicity remains unknown.Case Report: We present the six-year clinical course of a patient treated upfront with low-dose enzalutamide (25% of the standard dose). Despite initial disease control and tolerance, the patient developed progressive frailty and signs of severe androgen deprivation near end-of-life.Conclusion: This case illustrates that while low-dose enzalutamide can provide durable disease control in elderly patients with metastatic castration-resistant prostate cancer, it does not fully prevent the late-onset toxicities associated with androgen deprivation. Personalized treatment strategies – including dose adjustment over time and consideration of intermittent therapy – may help to balance efficacy with quality of life.